Morgan Stanley: Maintains HANSOH PHARMA (03692) "Shareholding" rating, Target Price raised to 25 Hong Kong dollars.

HANSOH PHARMA has set a sales target of 6 billion yuan for this year, indicating that there is room for upward revision of previous estimates, and that growth will accelerate this year.

Zhitong Finance31minutes ago

Deutsche Bank: Raises HANSOH PHARMA (03692) Target Price to HKD 24.7, Bullish on Innovative Drugs portfolio potential.

The statement indicates that the company has successfully transformed into a company focused on Innovative Drugs and has demonstrated its research and development capabilities by continuously licensing its pipeline Assets to leading Global pharmaceutical companies.

Zhitong Finance01:50 ET

Hong Kong stocks fluctuate | HANSOH PHARMA (03692) rises more than 3% again, the company's gross margin for Innovative Drugs last year expanded to 91%, and Ameliorate performed excellently.

HANSOH PHARMA (03692) rose over 3% again, as of the time of writing, it rose 2.22%, reported at 20.75 Hong Kong dollars, with a transaction amount of 85.3552 million Hong Kong dollars.

Zhitong Finance23:26 ET

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$19.86 From HK$18.36, Keeps at Neutral

MT NewswiresMar 24 05:05 ET · Ratings

Hansoh Pharmaceutical's 2024 Profit Jumps 33%

MT NewswiresMar 24 04:28 ET

UBS Group: Raised the Target Price of HANSOH PHARMA (03692) to HKD 24. Management anticipates that the contribution from Innovative Drugs will account for over 80%.

The management's goal for this year is to achieve sales of 6 billion yuan for Ameile, benefiting from the expansion of indications and supportive combination use scenarios; it is estimated that Ameile's peak sales may reach 8 billion yuan.

Zhitong FinanceMar 24 03:37 ET